Elevar Therapeutics Announces Rivoceranib Demonstrated Clinical Effectiveness in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma in a Phase 2 Trial Results of open-label, multicenter study will be presented during a poster session at ASCO on June 6 Rivoceranib represents a potential new treatment option for patients with R/M ACC who have...

Vitality Biopharma Receives $8.5 Million Common Stock Financing Financing to support company at least into 2020 and for the initiation of multiple Phase 2 clinical trials LOS ANGELES, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB: VBIO)...